Tenon Medical, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
TNON$1.640.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
Condensed Balance Sheets (Unaudited)
(In thousands, except share data)
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $3,442 | $6,535 |
| Accounts receivable, net | 1,311 | 863 |
| Inventory, net | 1,364 | 606 |
| Prepaid expenses and other current assets | 428 | 206 |
| Total current assets | 6,545 | 8,210 |
| Property and equipment, net | 663 | 752 |
| Deposits | 51 | 51 |
| Operating lease right-of-use asset | 200 | 399 |
| Deferred offering costs | — | 431 |
| Intangible assets, net | 500 | — |
| Goodwill (Note 3) | 2,407 | — |
| TOTAL ASSETS | $10,366 | $9,843 |
| Liabilities and Stockholders’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $625 | $369 |
| Accrued expenses | 1,514 | 910 |
| Current portion of accrued commissions | 686 | 303 |
| Current portion of operating lease liability | 216 | 287 |
| Total current liabilities | 3,041 | 1,869 |
| Accrued commissions, net of current portion | 1,516 | 1,862 |
| Operating lease liability, net of current portion | — | 141 |
| Contingent consideration (Note 3) | 1,011 | — |
| Total liabilities | 5,568 | 3,872 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Series A convertible preferred stock, $0.001 par value; 4,500,000 shares authorized at September 30, 2025 and December 31, 2024; 204,159 and 256,968 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 2,622 | 3,300 |
| Series B convertible preferred stock, $0.001 par value; 491,222 shares authorized at September 30, 2025 and December 31, 2024; 86,454 shares issued and outstanding at September 30, 2025 and December 31, 2024 | 452 | 452 |
| Common stock, $0.001 par value; 130,000,000 shares authorized at September 30, 2025 and December 31, 2024; 8,605,508 and 3,138,804 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 9 | 3 |
| Additional paid-in capital | 80,185 | 70,962 |
| Accumulated deficit | (78,470) | (68,746) |
| Total stockholders’ equity | 4,798 | 5,971 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $10,366 | $9,843 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.